apixaban/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“When the cardiovascular outcomes were assessed, no significant change was observed in all-cause mortality (OR: 1.12, 95% CI: 0.89–1.40; P =.33), MACEs (OR: 0.96, 95% CI: 0.82–1.14; P =.67), stroke (OR: 0.73, 95% CI: 0.44–1.20; P =.22), stent thrombosis (OR: 0.72, 95% CI: 0.47–1.12; P =.15), and MI (OR: 0.92, 95% CI: 0.75–1.13; P =.44) when apixaban was added to DAPT as shown in Figure 4.”
Quoted verbatim from Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.. - Study
- meta-analysis
- Population
- Patients with acute coronary syndrome, pooled across 4 RCTs; apixaban plus aspirin and clopidogrel (DAPT) versus DAPT alone
Effect 1.12 odds ratio, 95% CI 0.89 to 1.4
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.2021PMID:33761699Permalink
Keep reading
- Everything the graph holds on apixaban
- Every compound studied against All-cause mortality
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45FTGZQHFAAGYEJ2FPWGGBJ